Linked Data API

Show Search Form

Search Results

1132282
star this property registered interest false more like this
star this property date less than 2019-06-14more like thismore than 2019-06-14
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Genetics: Screening more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of patients that will benefit from whole genome sequencing in the first year of its introduction; and what steps is he taking to ensure the adequacy of trained professionals to provide that service. more like this
star this property tabling member constituency Sheffield South East more like this
star this property tabling member printed
Mr Clive Betts more like this
star this property uin 264725 remove filter
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-06-19more like thismore than 2019-06-19
star this property answer text <p>As part of the NHS Long Term Plan, the National Health Service has committed to sequencing 500,000 whole genomes by 2023/24.</p><p>During 2019, the NHS will begin to offer whole genome sequencing (WGS) as part of clinical care for:</p><p>- Seriously ill children likely to have a rare genetic disorder;</p><p>- People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test;</p><p>- People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS – children with cancer, sarcoma and Acute Myeloid Leukaemia.</p><p> </p><p>As the price of whole genome sequencing falls and the evidence improves, we envisage that it will be extended to more conditions and therefore more patients.</p> more like this
unstar this property answering member constituency Gosport more like this
star this property answering member printed Caroline Dinenage more like this
star this property question first answered
less than 2019-06-19T16:17:13.117Zmore like thismore than 2019-06-19T16:17:13.117Z
star this property answering member
4008
star this property label Biography information for Caroline Dinenage more like this
star this property tabling member
394
star this property label Biography information for Mr Clive Betts more like this